BioPharm, Bullish on India - eNewsletter
Verticaltalk Pharma e-Newsletter
Volume 3 No.1  2008
Best of 2007
Pharma Focus Asia | Issue 5 | 2007
Pharma Focus Asia - Media Pack
  Pharma Focus Asia News - Current Issue Magazine Archives
  Pharma Focus Asia - News Roundup News Roundup
Pharmalink gets the marketing rights to Eli Lilly's Distaclor® (Cefaclor) Pfizer Japan receives manufacturing authorisation for Champix®
Procter & Gamble Pharmaceuticals and Dong Wha and Form Alliance for Osteoporosis Treatments Arno Therapeutics enters agreement to develop cancer compounds
  Pharma Focus Asia - Events Pharma Events
2007 APEC Biotechnology Conference, July 23, 2007 The Biology of Embryonic & Adult Stem Cells
Feb 23 - 24, 2008
2007 APEC Biotechnology Conference, July 23, 2007 Impact India, New Delhi
Feb 04 - 07, 2008
PharmaPack, Chennai, India BioAsia 2008, Hyderabad, India
Feb 07 - 09, 2008
 
  Pharma Focus Asia - Press Releases Pharma Press Releases
Azur Pharma Announces the Acquisition of FazaClo for $42 Million Plus Contingent Milestones Synta and GlaxoSmithKline Announce Elesclomol Granted Orphan Drug Designation by the FDA
Caraco Pharmaceutical Laboratories, Announces FDA Approval to Market Generic Version of Paxil(R) FDA Approves MiddleBrook's Amoxicillin PULSYS for Pharyngitis/Tonsillitis in Adolescents and Adults
Current Issue   |   Archives   |   Advertise
In this issue of The Pharma Edge
Pharma Focus Asia - Articles Articles - Best of 2007
     
Challenges for Pharmaceutical Sales Forces - Lessons from other sectors
Reinhard Angelmar, The Salmon and Rameau Fellow Healthcare Management and Professor of Marketing, INSEAD, France
Manufacturing Control Systems - The "next big thing" for the life sciences industry
Mark Albano, Life Sciences Marketing Manager, Honeywell, USA
Rajeev Joshi, Manager, Development Engineering, Honeywell, USA
Getting to the Heart of a Tumor Cell - Targeting the nucleus
David Andrew Jans, Professor & Head, Monash University, Australia
Kylie M Wagstaff, Post-doctoral Researcher, Monash University, Australia
Biomedical Polymers - Drug delivery and molecular imaging
Susan Bassion, CDISC Lab Team Leader, CDISC, USA
Information Technology - Right prescription for the growth of pharmaceutical companies
Sourabh Kankhar, Research Analyst, Life Science Practice - Asia Pacific, Frost & Sullivan, Singapore
Foreign Biotech Trials in Asia - Emerging trends
Shonagh Mc Vean, Partner, Gilbert's LLP, Canada
Sara Zborovski, Lawyer, Gilbert's LLP, Canada
Redesigning Drugs to Enhance Performance
Luigi G Martini, Director, Process Technologies, GlaxoSmithKline, UK
Patrick J Crowley, Vice President, Pharmaceutical Development, GlaxoSmithKline, USA
The Indian Pharmaceutical Industry - Promises and perils
Utkarsh Palnitkar, National Leader, Health Sciences Industry Practice, Ernst & Young, India
Innovation - The Key Driver
Glenn Saldanha, CEO, Glenmark Pharmaceuticals Limited, India
A New Paradigm for the Indian Pharma Industry
Swati A. Piramal, Director, Strategic Alliances & Communications, Nicholas Piramal India Limited, India
Biopharm - Bullish on India
Jim Worrell, CEO, Pharma Services Network, USA
Orphan Drugs - Asia, The New Frontier
Mary Dunkle, Vice President, Communications, National Organization for Rare Disorders, Connecticut, USA
Generics Market in Asia - Opportunities and Challenges
C R Chenthir K, CEO, Plutus Pharma Network Pvt. Ltd. , India
Asia - The Emerging Pharma R&D Hub
Rajeshwer Chigullapalli and Feroz Zaheer, Editorial Team, Pharma Focus Asia
   
Pharma Focus Asia - Projects Research Insights Pharma Focus Asia - TechnoTrends TechnoTrends Pharma Focus Asia - Industry Reports Industry Reports
Thermoresponsive Drug Delivery Using Liquid Crystal-Embedded Cellulose Nitrate Membranes

The aim of this study was to investigate the use of thermotropic liquid crystalline (TLC) blends of 4-pentyl-4'-cyanobiphenyl (K15) and 4-heptyl-4'-cyanobiphenyl (K21) with appropriate nematic to isotropic phase temperature (Tn - i) just above body temperature as a temperature-modulated drug permeation system.
Pharmacovigilance program to monitor adverse reactions of recombinant streptokinase in acute myocardial infarction

Streptokinase (SK) is an effective fibrinolytic agent for the treatment of acute myocardial infarction (AMI). The objective of the present study was to assess the adverse drug reactions (ADRs) associated with intravenous recombinant SK in patients with AMI in routine clinical practice. Elements to define causality were documented.
More Research Insights
Air-Cooled Peltier Accessories for Accurate Temperature Control

Peltier devices are small, solid-state devices that control temperature to cater to the requirement of pharmaceutical and life science assays for accurate and constant temperature controlin order to acquire meaningful data.
New Technology for Determining the Cardiac Safety Profile of Drugs

COMPAS gives new insights into drug’s cardiac safety profile by providing comprehensive set of ECG analysis services and ensuring an in-depth characterization of a new drug’s cardiac safety profile based on the repolarisation segment from the surface ECGs.
First Ever Syringe leak testing machine by Bonfiglioli Pharma Machinery

The new leak tester to be launched by Bonfiglioli Pharma Machinery will be the first in the market and can be customised to the requirements of the client.
More TechnoTrends
Pharma 2020: The vision-Which path will you take?
A Report by PricewaterhouseCoopers

By 2020, the context in which Pharma operates will be very different from that which prevails today. And one of the recurring motifs in all the shifts described is globalisation. The globalisation of the markets, as demand for medicine rises in the developing world; the globalisation of R&D, as a growing share of R&D migrates to Asia; the globalisation of the regulations governing the development of new medicines, as national and federal agencies collaborate.
A Report by Datamonitor

As pressures on the blockbuster model increase in terms of the perceived failure to harness R&D innovation, increased generic threat and greater P&R hurdles for me-too drugs, drug developers are turning to niche indications for future sales growth.Drugs companies should focus on characterizing the target market to drive clinical trial progression, approval and successful uptake.
More Reports
Send this newsletter to a friend or colleague.
Your Name: Friend's Name: Email:
You are receiving this email because you are either a registered member or requested for a newsletter from Verticaltalk Pharma.
To SUBSCRIBE
QUESTIONS: For questions or assistance, please contact our Customer Support Staff : verticaltalkpharma@ochre-media.com
PRIVACY: View our Privacy Policy
Copyright © 2008 Ochre Media Private Limited. All rights reserved.
Pharma Focus Asia - Clinical Trials Market in Japan IMS